We conducted this retrospective study to investigate whether microwave ablation (MWA) of primary tumor sites plus epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) could improve survival in advanced non small cell lung cancer (NSCLC) with EGFR mutations. MWA was conducted at the primary tumor sites, followed by EGFR-TKIs in the MWA plus EGFR-TKIs group. EGFR-TKIs were administered until disease progression or intolerable toxicity. The primary endpoint was progressionfree survival (PFS); secondary endpoints were overall survival (OS) and objective response rate (ORR) 
INTRODUCTION
EGFR sensitive mutations, especially in-frame deletions in exon 19 and a point mutation in exon 21 (L858R), are present in 30-40% of non-small cell lung cancer (NSCLC) patients and respond well to EGFRTKIs such as gefitinib and erlotinib. It is estimated that the ORR ranged from 60% to 83%, with a median PFS of 8 to 11 months. [1] [2] [3] [4] [5] Patients who respond to EGFR-TKIs will develop resistance eventually. Several mechanisms had been clarified; among them, an EGFR T790M mutation in exon 20 [6] [7] [8] [9] and c-MET [10, 11] amplifications have been explored widely, and account for 50% and 25% of all resistant mechanisms, respectively. What is more, PIK3CA mutation, [12] ERBB2 amplification, [13] HGF overexpression, [14] AXL activation, [15] epithelial-mesenchymal transition, and pathology type transformation, especially adenocarcinoma transformation into small cell lung cancer, have also been reported as causes of secondary resistance to EGFR-TKIs. [16] [17] [18] According to the progression of EGFR-TKIs, secondary resistance can be clarified into three types: intracranial disease progression, development of asymptomatic oligometastases, and symptomatic disease progression. [19, 20] For the former two types, EGFR-TKIs could be continued after local therapy is administered. [21, 22] For patients with intracranial progression, both whole-brain radiation therapy (WBRT) and stereotactic radiotherapy (SRT) could be treatment regimens. [20] [21] [22] For patients with oligometastases other than intracranial metastases, radiation therapy or thermal ablation could be applied. [20, [23] [24] [25] Ni et al. showed that patients with extra-central nervous system oligoprogressive disease had a median PFS of 8.8 months after microwave ablation (MWA), which was significantly different when compared with a transformation to platinum-based doublet chemotherapy. [25] In previous studies, we verified that advanced NSCLC could benefit from a combination of MWA at primary tumor sites and platinum-based doublet chemotherapy. [26] What is more, a significant difference in PFS was also observed when compared with chemotherapy alone. [27] A recent phase II prospective, randomized, controlled clinical trial verified that local consolidative therapy with maintenance therapy for patients with three or fewer metastases from NSCLC (those who benefit from first-line systematic therapies) and demonstrated improved PFS when compared with maintenance therapy alone. The median PFS were 11.9 months and 3.9 months for consolidative plus maintenance therapy and maintenance therapy alone, respectively. [28] Local therapy including radiation and MWA in combination with systematic therapies improve survival in advanced NSCLC. Therefore, we conducted this retrospective study to determine whether advanced NSCLC patients with EGFR-sensitive mutations could benefit from MWA at primary tumor sites plus EGFRTKIs when compared with EGFR-TKIs alone.
RESULTS

Patient characteristics
From January 25, 2010 to May 19, 2016 , 58 patients were enrolled, of whom 34 were in the MWA plus EGFR-TKIs group and 24 were in the EGFRTKIs group. In the MWA plus EGFR-TKIs group, 26 were women, 13 were aged 65 years or older, 33 had adenocarcinoma histology and an ECOG PS of 1, and 28 were nonsmokers. EGFR mutations included 18 19Del mutations and 19 exon 21 L858R mutations (including 3 patients with both 19Del mutations and L858R mutations). Nineteen patients were treated with EGFRTKIs as a first-line therapy and 15 patients were treated with EGFR-TKIs as a post-first-line therapy. The primary tumor size ranged from 0.8 to 9.0 cm, with a mean of 3.7 cm. Most patients (23 patients, 67.6%) underwent ablation with two antennas and the typical ablation energy was 70 W (23 patients, 67.6%). In the EGFRTKIs group, 13 were women aged 65 years or older, 23 had adenocarcinoma histology, 21 had an ECOG PS of 1, and 17 were nonsmokers. EGFR mutations included 16 19Del mutations and 10 exon 21 L858R mutations (including two patients with both mutations). Sixteen patients were treated with EGFR-TKIs as a first-line therapy, and 8 patients were treated with EGFR-TKIs as a post-first-line therapy. The primary tumor size ranged from 1.6 to 8.8 cm, with a mean of 3.9 cm. Baseline characteristics of the enrolled patients are shown in detail in Table 1 .
Response to MWA and EGFR-TKIs
Complete ablation was achieved in 29 (Table 2) .
In the multivariate analyses of PFS and OS, MWA was not a significant prognostic factor, and the corresponding p-values were 0. In order to explore the correlation between the number of tumor sites and the survival benefit of MWA, we divided patients into two groups, those with three or fewer tumor metastases and those with more than three tumor sites other than the primary tumor in advanced. No differences were observed in either group in PFS or OS (Figures 3-6 ). For patients with more than three tumor metastases, the median PFS were 11.3 months (95% CI, 3.1-22.9 months) and 15.1 months (95% CI, 8.1-22.2 months) (p = 0.874) ( Figure  3 ) for the MWA plus EGFR-TKIs group and the EGFRTKIs group, respectively, and the corresponding OS were 28.4 months (95% CI, 18.1-38.6 months) and 18.2 months (95% CI, 15.1-21.2 months) (p = 0.859), (Figure 6 ).
DISCUSSION
EGFR-TKIs remain the standard of care for advanced NSCLC with EGFR-sensitive mutations and show a dramatic improvement in PFS. [1] [2] [3] [4] [5] However, all patients will develop resistance ultimately, even those who achieve complete or incomplete remission. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Multiple studies explored the following treatment strategy after the failure of EGFR-TKIs. Based on the progression models, the therapies varied. [19, 20] For those with brain progression, SBRT or SRT was the first choice, and the EGFR-TKIs were continued. [20] [21] [22] For patients with local disease progression, local treatments including radiation or thermal ablation in combination with previous EGFR-TKIs were recommended [20, 23, 24, [33] [34] [35] . However, chemotherapy and transfer to a third EGFR-TKI were treatment options for those with widespread metastasis.
We firstly explored whether the combination of MWA at primary tumor sites and EGFR-TKIs could improve PFS when compared with EGFR-TKIs alone for advanced NSCLC with EGFR-sensitive mutations. No significant difference was observed in either PFS or OS in univariate and multivariate analyses, indicating that MWA and EGFR-TKIs did not have a synergistic effect, which was different from radiation plus EGFRTKIs. Welsh et al. [21] showed that patients with EGFR- sensitive mutations and brain metastases had superior survival and ORRs when treated with EGFR-TKIs and SBRT. William et al. [22] verified that the median OS and intracranial PFS were longer in the group treated with RT upfront compared with the group treated with EGFR-TKIs upfront. What is more, Zeng et al. [36] showed that concomitant administration of gefitinib and WBRT was found to result in higher treatment response and disease control rates in patients with EGFR-sensitive mutations and NSCLC brain metastases compared with gefitinib alone. Hong et al. [33] found that in NSCLC patients with EGFR-sensitive mutations and skeletal metastasis progression, EGFR-TKIs continued in combination with radiation after treatment with EGFR-TKIs and disease progression resulted in a PFS of 5.6 to 8.0 months. Isolated bone failure without systemic disease progression is associated with better survival when treated with continuation of EGFR-TKIs plus local radiation. [24] Studies verified that EGFRTKIs could modulate the radiation response. [37, 38] When combined with radiation, EGFR-TKIs promote a further reduction in the S-phase fraction, resulting in an accumulation of cells in G1 and G2. [37] What is more, TKIs enhance the induction of apoptosis, inhibit EGFR autophosphorylation and Rad51 expression, and improve radiosensitivity. [37] EGFR inhibition led to pronounced cellular senescence of irradiated cells. Moreover, cellular senescence is a prominent mechanism in radiosensitization. The senescence and radiosensitization were linked to an increase in residual radiation-induced DNA double-strand breaks irrespective of p53/p16 status. [39] To explore the correlation between the number of tumor sites and the survival benefit of MWA, we divided patients into two groups, those with three or fewer tumor metastases and those with more than three tumor sites other than the primary tumor in advanced. No differences were observed in either group in PFS or OS. Gomez et al. [28] showed that advanced NSCLC patients without driver mutations after systematic treatments of platinum-based doublet chemotherapy and patients with driver mutations after EGFR-TKIs or ALK inhibitors had longer PFS when treated with consolidated treatments followed by maintenance treatments compared with maintenance treatments alone. An 8-month PFS was observed, which was significantly different. However, the study was restricted to those with oligometastases, which was defined as no more than three tumor sites. Chiang et al. [34] also showed that radical palliative thoracic RT was safe and might be beneficial for primary lung lesions in patients with metastatic NSCLC and controlled extrathoracic diseases. The median OS, PFS after RT, and OS after RT were 50 months, 15 months, and 18 months, respectively. Qin et al. [35] reported that when patients who responded to EGFR-TKIs received EGFR-TKIs and local radiofrequency hyperthermia, the PFS and OS were 22 months and 26 months, respectively. The difference in PFS indicated that local treatments, which did not focus on all tumor sites, did not have a survival advantage for patients with EGFR-sensitive mutations treated with MWA plus EGFR-TKIs.
In conclusion, for advanced NSCLC patients with EGFR-sensitive mutations, MWA at the primary tumor sites plus EGFR-TKIs failed to show a survival advantage when compared with EGFR-TKIs alone.
MATERIALS AND METHODS
Patient characteristics
Patients with pathologically verified advanced NSCLC and EGFR-sensitive mutations, i.e., an exon 19 deletion or exon 21 L858R point mutation, were recruited. Other inclusion criteria included an age no less than 18 years; Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1; no local therapy at primary tumor sites, such as radiation, radiofrequency ablation (RFA), or I125 radioactive particle implantation; and adequate bone marrow, hepatic, and renal function. The exclusion criteria were as follows: serious issues with pulmonary and cardiovascular function such that MWA could not be risked; previous treatment with EGFR-TKIs or local therapies for primary tumors; baseline interstitial lung disease; cerebral hemorrhage, cerebral infarction, or coronary heart disease, especially unstable angina or myocardial infarction during the previous 6 months; and anti-platelet or anti-necrosis treatments during the past 1 week.
The study was approved by the ethics committee of Shandong Provincial Hospital affiliated with Shandong University prior to study enrollment. Written informed consent was obtained from all enrolled patients.
MWA procedure
All patients allocated to the MWA plus EGFRTKIs group received MWA at primary tumor sites under computed tomography guidance. The procedure has been detailed in our previous reports. [25, 26, 29] EGFR mutation testing DNA was extracted from 4-μm formalin-fixedand parrffin-embedded,(FFPE) tumor slides by using the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany) according to the manufacturer's instructions. The EGFR mutation testing procedure was described in detail in our previous study. [30] A classic S-curve and a Ct value >30 were considered to be a positive result, indicating the presence of a mutation. www.impactjournals.com/oncotarget
EGFR-TKIs
Patients received 250 mg oral gefitinib or 150 mg erlotinib once daily until disease progression or intolerable toxicity. The interval between MWA and EGFR-TKIs therapy was 1 week.
The follow-up and response evaluation MWA follow-up was performed every month for 3 months post-ablation and at 3-month intervals thereafter. The response to EGFR-TKIs was evaluated 1 month later and then at 2-month intervals.
The response to MWA was assessed according to a Chinese expert consensus [31] . The response to EGFRTKIs was conducted according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [32] .
Statistical analyses
SPSS version 17.0 (USA) was applied for statistical analyses. The primary endpoint was PFS; the secondary endpoint was overall survival (OS). PFS was calculated from the date of MWA to disease progression for both primary tumor sites and other tumor sites or death for those treated with MWA plus EGFR-TKIs. For patients who received EGFR-TKIs only, PFS was calculated from the start of treatment with EGFR-TKIs to disease progression or death. OS was calculated from the diagnosis of NSCLC to death from any cause. Both PFS and OS were analyzed using Kaplan-Meier univariate analyses and Cox regression multivariate analyses. Factors with p-values less than 0.5 in the univariate analyses besides MWA were examined in the Cox regression multivariate analyses. Chi-square test was used to test the correlation between the response to EGFR-TKIs and the treatment regimens. All tests were two-sided, and p-values less than 0.05 were considered to represent a significant difference.
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